The aim of this work was to analyse the role of several factors (personality traits, previous prolonged experiences of smoking abstinence, nicotinic dependence, administration of pharmacological treatment, presence of psychopathology or the sex of the smoker) in the abstinence at 9 months after completion of the treatment to stop smoking.

The sample consisted in 249 adults (91 men and 158 women), with an average age of 46.37 years (range = 23-69 years) who voluntarily participated in a treatment to stop smoking (10 sessions in 3 months). Prior to commencing the treatment, they signed the commitment and informed consent. For the purpose of analysis, the subjects were asked to complete the following tests at the beginning of the study: a semi-structured interview, to measure the psychopathology and their tobacco habit; personality questionnaire (Big Five Questionnaire) and the nicotinic dependence measure (Fagerström test). Consumption measures were also taken at the end of treatment (T1) and 9 months after completion (T2). The results obtained showed that in T1, 83.7% of the participants who completed the treatment, had stopped smoking in T2, 52% still did not smoke. On the question of pharmacological treatment with Varenicline, this study sounds that it favoured the completion of treatment, but did not affect the abstinence in T2.

By means of binary logistic regression analysis, explaining between 12% and 16% of the variance, it was found that sex (in favour of males), the absence of psychopathology, the low level of nicotinic dependence, previous experience without smoking and greater tenacity in the personality questionnaire, predicted the 79.4% of the non-smoking participants in T2.

This study concludes that personality factors (tenacity), previous experience of success greater than 6 months, absence of psychopathology, low nicotine dependence and male sex emerged as reliable predictors of success of the treatment to stop smoking.